Share
2,062 Posts.
lightbulb Created with Sketch. 509
clock Created with Sketch. 30/03/22
17:44
Share
Originally posted by FreeBobby2002:
↑
Looks good, considering buying soon. Yet another biotech getting unfairly battered due to overall sentiment when there is nothing wrong with the company. Quite undervalued IMO. Merck's competitor cholesterol drug seems to be on par (and is actually validated in humans), so NYR is behind, but in such a huge space, there may be enough room for more than one player. Even if it is not first to market, clinical progression of the asset should warrant a much higher MC than $33m AUD regardless.
Expand
Absolutely......The market is so huge that multiple players have enough room to make some decent returns.....
(20min delay)